Is OTLK or MREO more profitable?

Oncobiologics' return on equity of 0.00% beat Mereo BioPharma Group's return on equity. Company Net Margins Return on Equity Return on Assets Oncobiologics N/A N/A -254.82% Mereo BioPharma Group N/A -74.82% -64.28%

Is MREO or TNYA more profitable?

Mereo BioPharma Group's return on equity of -74.82% beat Tenaya Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Mereo BioPharma Group N/A -74.82% -64.28% Tenaya Therapeutics N/A -83.75% -66.53%

Which has higher valuation & earnings, KZIA or MREO?

Novogen has higher earnings, but lower revenue than Mereo BioPharma Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $30K 4,837.81 -$13.41M N/A N/A Mereo BioPharma Group $500K 89.43 -$41.88M -$0.04 N/A

Is KZIA or MREO more profitable?

Novogen's return on equity of 0.00% beat Mereo BioPharma Group's return on equity. Company Net Margins Return on Equity Return on Assets Novogen N/A N/A N/A Mereo BioPharma Group N/A -74.82% -64.28%

Is INO or MREO more profitable?

Mereo BioPharma Group's return on equity of -74.82% beat Inovio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Inovio Pharmaceuticals N/A -669.94% -73.97% Mereo BioPharma Group N/A -74.82% -64.28%

Is MREO or BMEA more profitable?

Mereo BioPharma Group's return on equity of -74.82% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Mereo BioPharma Group N/A -74.82% -64.28% Biomea Fusion N/A -253.73% -97.91%

Mereo BioPharma Group (MREO) Competitors

$0.28 +0.04 (+14.47%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$0.28 0.00 (0.00%)

As of 09/11/2026 07:53 PM Eastern

Compare

MREO vs. OTLK, TNYA, KZIA, INO, and BMEA

Should you buy Mereo BioPharma Group stock or one of its competitors? Mereo BioPharma Group's main competitors and comparable companies include Oncobiologics (OTLK), Tenaya Therapeutics (TNYA), Novogen (KZIA), Inovio Pharmaceuticals (INO), and Biomea Fusion (BMEA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Mereo BioPharma Group compare to Oncobiologics?

Oncobiologics (NASDAQ:OTLK) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Oncobiologics has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

Oncobiologics currently has a consensus price target of $5.20, indicating a potential upside of 687.88%. Mereo BioPharma Group has a consensus price target of $1.67, indicating a potential upside of 495.24%. Given Oncobiologics' stronger consensus rating and higher possible upside, equities analysts plainly believe Oncobiologics is more favorable than Mereo BioPharma Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are held by institutional investors. 1.8% of Oncobiologics shares are held by company insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Oncobiologics had 6 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 7 mentions for Oncobiologics and 1 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 0.94 beat Oncobiologics' score of 0.36 indicating that Mereo BioPharma Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Oncobiologics	Neutral
Mereo BioPharma Group	Positive

Mereo BioPharma Group has lower revenue, but higher earnings than Oncobiologics. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	119.02	-$62.42M	-$0.77	N/A
Mereo BioPharma Group	$500K	89.43	-$41.88M	-$0.04	N/A

Oncobiologics' return on equity of 0.00% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-254.82%
Mereo BioPharma Group	N/A	-74.82%	-64.28%

Summary

Oncobiologics beats Mereo BioPharma Group on 8 of the 15 factors compared between the two stocks.

How does Mereo BioPharma Group compare to Tenaya Therapeutics?

Mereo BioPharma Group (NASDAQ:MREO) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

Mereo BioPharma Group presently has a consensus target price of $1.67, suggesting a potential upside of 495.24%. Tenaya Therapeutics has a consensus target price of $4.00, suggesting a potential upside of 525.00%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tenaya Therapeutics is more favorable than Mereo BioPharma Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Mereo BioPharma Group has higher revenue and earnings than Tenaya Therapeutics. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group	$500K	89.43	-$41.88M	-$0.04	N/A
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.53	N/A

In the previous week, Tenaya Therapeutics had 3 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 4 mentions for Tenaya Therapeutics and 1 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 0.94 beat Tenaya Therapeutics' score of 0.71 indicating that Mereo BioPharma Group is being referred to more favorably in the media.

Company	Overall Sentiment
Mereo BioPharma Group	Positive
Tenaya Therapeutics	Positive

62.8% of Mereo BioPharma Group shares are owned by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 6.5% of Mereo BioPharma Group shares are owned by insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Mereo BioPharma Group has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market. Comparatively, Tenaya Therapeutics has a beta of 2.77, indicating that its stock price is 177% more volatile than the broader market.

Mereo BioPharma Group's return on equity of -74.82% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group	N/A	-74.82%	-64.28%
Tenaya Therapeutics	N/A	-83.75%	-66.53%

Summary

Tenaya Therapeutics beats Mereo BioPharma Group on 8 of the 15 factors compared between the two stocks.

How does Mereo BioPharma Group compare to Novogen?

Novogen (NASDAQ:KZIA) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Novogen currently has a consensus price target of $27.33, indicating a potential upside of 144.27%. Mereo BioPharma Group has a consensus price target of $1.67, indicating a potential upside of 495.24%. Given Mereo BioPharma Group's higher probable upside, analysts clearly believe Mereo BioPharma Group is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

Novogen's return on equity of 0.00% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Mereo BioPharma Group	N/A	-74.82%	-64.28%

Novogen has a beta of 2.14, indicating that its stock price is 114% more volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

30.9% of Novogen shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 1.0% of Novogen shares are owned by company insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Novogen has higher earnings, but lower revenue than Mereo BioPharma Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	4,837.81	-$13.41M	N/A	N/A
Mereo BioPharma Group	$500K	89.43	-$41.88M	-$0.04	N/A

In the previous week, Novogen had 4 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 5 mentions for Novogen and 1 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 0.94 beat Novogen's score of 0.17 indicating that Mereo BioPharma Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Novogen	Neutral
Mereo BioPharma Group	Positive

Summary

Novogen beats Mereo BioPharma Group on 8 of the 13 factors compared between the two stocks.

How does Mereo BioPharma Group compare to Inovio Pharmaceuticals?

Inovio Pharmaceuticals (NASDAQ:INO) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

26.8% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are held by institutional investors. 1.7% of Inovio Pharmaceuticals shares are held by company insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Inovio Pharmaceuticals has a beta of 1.63, suggesting that its share price is 63% more volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market.

In the previous week, Inovio Pharmaceuticals had 7 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 8 mentions for Inovio Pharmaceuticals and 1 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 0.94 beat Inovio Pharmaceuticals' score of 0.66 indicating that Mereo BioPharma Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Inovio Pharmaceuticals	Positive
Mereo BioPharma Group	Positive

Inovio Pharmaceuticals presently has a consensus target price of $3.17, indicating a potential upside of 153.33%. Mereo BioPharma Group has a consensus target price of $1.67, indicating a potential upside of 495.24%. Given Mereo BioPharma Group's higher probable upside, analysts clearly believe Mereo BioPharma Group is more favorable than Inovio Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

Mereo BioPharma Group has higher revenue and earnings than Inovio Pharmaceuticals. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$60K	2,154.17	-$84.95M	-$0.91	N/A
Mereo BioPharma Group	$500K	89.43	-$41.88M	-$0.04	N/A

Mereo BioPharma Group's return on equity of -74.82% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%
Mereo BioPharma Group	N/A	-74.82%	-64.28%

Summary

Mereo BioPharma Group beats Inovio Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Mereo BioPharma Group compare to Biomea Fusion?

Mereo BioPharma Group (NASDAQ:MREO) and Biomea Fusion (NASDAQ:BMEA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Mereo BioPharma Group's return on equity of -74.82% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group	N/A	-74.82%	-64.28%
Biomea Fusion	N/A	-253.73%	-97.91%

In the previous week, Biomea Fusion had 1 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 2 mentions for Biomea Fusion and 1 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 0.94 beat Biomea Fusion's score of 0.85 indicating that Mereo BioPharma Group is being referred to more favorably in the media.

Company	Overall Sentiment
Mereo BioPharma Group	Positive
Biomea Fusion	Positive

62.8% of Mereo BioPharma Group shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 6.5% of Mereo BioPharma Group shares are held by company insiders. Comparatively, 10.6% of Biomea Fusion shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Mereo BioPharma Group presently has a consensus price target of $1.67, suggesting a potential upside of 495.24%. Biomea Fusion has a consensus price target of $9.00, suggesting a potential upside of 417.24%. Given Mereo BioPharma Group's higher probable upside, research analysts plainly believe Mereo BioPharma Group is more favorable than Biomea Fusion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Mereo BioPharma Group has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.23, indicating that its share price is 123% less volatile than the broader market.

Mereo BioPharma Group has higher revenue and earnings than Biomea Fusion. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group	$500K	89.43	-$41.88M	-$0.04	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$0.29	N/A

Summary

Mereo BioPharma Group beats Biomea Fusion on 8 of the 14 factors compared between the two stocks.

Get Mereo BioPharma Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MREO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MREO vs. The Competition

Export

Metric	Mereo BioPharma Group	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$44.71M	$3.86B	$7.16B	$12.85B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-7.00	8.41	214.39	20.85
Price / Sales	89.43	1,378.88	633.80	90.72
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	1.08	15.12	10.33	6.21
Net Income	-$41.88M	-$22.86M	$3.50B	$358.54M
7 Day Performance	12.00%	-4.34%	-3.32%	-2.35%
1 Month Performance	-9.00%	0.54%	-0.53%	-3.23%
1 Year Performance	-84.86%	40.74%	23.51%	8.79%

Mereo BioPharma Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MREO Mereo BioPharma Group	3.4947 of 5 stars	$0.28 +14.5%	$1.67 +495.2%	-84.9%	$44.71M	$500K	N/A	40	Gap Up High Trading Volume
OTLK Oncobiologics	3.3798 of 5 stars	$0.65 -2.3%	$5.20 +698.8%	-36.5%	$158.49M	$1.35M	N/A	20	Short Interest Increase
TNYA Tenaya Therapeutics	2.4171 of 5 stars	$0.70 +2.6%	$4.00 +470.6%	-46.7%	$157.63M	N/A	N/A	110	News Coverage Gap Up
KZIA Novogen	3.4524 of 5 stars	$12.04 -2.2%	$27.33 +127.0%	+39.9%	$156.35M	$30K	N/A	12	Analyst Forecast Short Interest Increase
INO Inovio Pharmaceuticals	3.2258 of 5 stars	$1.45 +1.0%	$3.17 +119.1%	-47.5%	$148.38M	$60K	N/A	320	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MREO) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mereo BioPharma Group (MREO) Competitors

MREO vs. OTLK, TNYA, KZIA, INO, and BMEA

How does Mereo BioPharma Group compare to Oncobiologics?

Summary

How does Mereo BioPharma Group compare to Tenaya Therapeutics?

Summary

How does Mereo BioPharma Group compare to Novogen?

Summary

How does Mereo BioPharma Group compare to Inovio Pharmaceuticals?

Summary

How does Mereo BioPharma Group compare to Biomea Fusion?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MREO vs. The Competition

Mereo BioPharma Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mereo BioPharma Group (MREO) Competitors

MREO vs. OTLK, TNYA, KZIA, INO, and BMEA

How does Mereo BioPharma Group compare to Oncobiologics?

Which has more risk and volatility, OTLK or MREO?

Do analysts recommend OTLK or MREO?

Do insiders and institutionals believe in OTLK or MREO?

Does the media prefer OTLK or MREO?

Which has higher valuation & earnings, OTLK or MREO?

Is OTLK or MREO more profitable?

Summary

How does Mereo BioPharma Group compare to Tenaya Therapeutics?

Do analysts rate MREO or TNYA?

Which has higher earnings & valuation, MREO or TNYA?

Does the media favor MREO or TNYA?

Do insiders and institutionals hold more shares of MREO or TNYA?

Which has more risk & volatility, MREO or TNYA?

Is MREO or TNYA more profitable?

Summary

How does Mereo BioPharma Group compare to Novogen?

Do analysts prefer KZIA or MREO?

Is KZIA or MREO more profitable?

Which has more risk and volatility, KZIA or MREO?

Do institutionals & insiders hold more shares of KZIA or MREO?

Which has higher valuation & earnings, KZIA or MREO?

Does the media prefer KZIA or MREO?

Summary

How does Mereo BioPharma Group compare to Inovio Pharmaceuticals?

Do insiders & institutionals hold more shares of INO or MREO?

Which has more risk & volatility, INO or MREO?

Does the media prefer INO or MREO?

Do analysts recommend INO or MREO?

Which has stronger earnings and valuation, INO or MREO?

Is INO or MREO more profitable?

Summary

How does Mereo BioPharma Group compare to Biomea Fusion?

Is MREO or BMEA more profitable?

Does the media prefer MREO or BMEA?

Do institutionals and insiders hold more shares of MREO or BMEA?

Do analysts rate MREO or BMEA?

Which has more risk & volatility, MREO or BMEA?

Which has higher valuation & earnings, MREO or BMEA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MREO vs. The Competition

Mereo BioPharma Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools